Cost-effectiveness analysis of pharmacogenetic-guided antiseizure medication therapy based on the risk of HLA-A*31:01 allele variants in Japan
{{output}}
Aim: Carbamazepine (CBZ) remains a common antiseizure medication for focal epilepsy but carries the risk of cutaneous adverse drug reactions (cADRs), including Stevens-Johnson syndrome and toxic epidermal necrolysis. The HLA-A*31... ...
